Contract Manufacturing Services

Sterling Pharma Signs Agreement to Support COVID-19 Treatment Development

July 29, 2020

Sterling Pharma Solutions has signed a deal with Moleculin Biotech to support the development of WP1122, a potential COVID-19 treatment.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.

Vetter Expands Fill/Finish Capacity with Acquisition of New Site in Austria

July 08, 2020

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

July 02, 2020

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

Demand for Custom Dosage Forms Fuels Innovation

July 02, 2020

Demand for custom drug delivery solutions is increasing and bringing forth an exciting period of valuable, innovative development opportunities.

Contractors Balance Increased Demand During COVID-19

July 02, 2020

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

Cambrex Expands Flexible Manufacturing Capacity in Sweden

July 01, 2020

Cambrex has invested in an expansion of its flexible manufacturing facility in Sweden, which will increase the company’s flexible drug substance manufacturing capacity.

Cobra Biologics to Manufacture AstraZeneca’s COVID-19 Vaccine Candidate

June 17, 2020

Cobra Biologics has signed a supply agreement to provide GMP manufacturing for AstraZeneca’s AZD1222 COVID-19 vaccine candidate.

CordenPharma Expands Lipid Supply for Moderna

June 04, 2020

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

Novavax Contracts to Expand Adjuvant Production

June 04, 2020

Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.